Anti-cd38 antibodies
AssigneeTakeda Pharmaceutical Company Limited
InventorsKathleen Ann Elias, Gregory Landes, Shewta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
Life of this patent
Estimating the term…
Abstract
Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
Claims13
A method of inhibiting the biological activity of human CD38 protein (SEQ ID NO:
- 1) by contacting said protein with an antibody that interacts with at least K121, F135, Q139, D141, E239, W241, C275, K276, F284, P291 and E292 of SEQ ID NO:1.
A method of treating an autoimmune disease comprising administering to a patient in need thereof an isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:
- a) a heavy chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:3;
- ii) a second CDR comprising SEQ ID NO:4;
- iii) a third CDR comprising SEQ ID NO:5;
- and
- b) a light chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:6;
- ii) a second CDR comprising SEQ ID NO:7;
- iii) a third CDR comprising SEQ ID NO:8.
Dependencies are inferred from the claim text.